AKT1 and breast carcinoma: In these trials, specific inhibitors of different isoforms of PI3K, pan PI3K inhibitors, Akt-inhibitors or mTOR-inhibitors are evaluated in different settings commonly in association with trastuzumab and chemotherapy to delay breast cancer progression and/or overcome resistance to trastuzumab.